Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

BeyondSpring (BYSI) announced that phase 2 IIT data on the first 30 patients dosed with plinabulin in the 303 Study of patients with non-small cell lung cancer after disease ... 57% patients with ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

GAITHERSBURG, Md., US, 06 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative ...

We've made massive strides against the deadly disease, but rates haven't fallen for people diagnosed with the disease who've never smoked.

MSK identified a new subtype of small cell lung cancer in young non-smokers, challenging existing treatment paradigms with ...

Most of these occur in adenocarcinoma non-small cell lung cancer. Gene testing can identify an EGFR mutation ... but some types of squamous cell carcinoma are also affected by the protein. In these ...

Learn about the questions to ask a lung cancer doctor after being diagnosed, from an MSK specialist who has successfully ...